These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 15284255)

  • 1. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA.
    Chan AT; Ma BB; Lo YM; Leung SF; Kwan WH; Hui EP; Mok TS; Kam M; Chan LS; Chiu SK; Yu KH; Cheung KY; Lai K; Lai M; Mo F; Yeo W; King A; Johnson PJ; Teo PM; Zee B
    J Clin Oncol; 2004 Aug; 22(15):3053-60. PubMed ID: 15284255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neo-adjuvant Docetaxel and Cisplatin followed by concurrent Cisplatin with radiation therapy in treatment of locally advanced nasopharyngeal carcinoma.
    Hassan E; Galal K; Esmat E
    Gulf J Oncolog; 2008 Jan; (3):46-53. PubMed ID: 20084797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group.
    Chua DT; Sham JS; Choy D; Lorvidhaya V; Sumitsawan Y; Thongprasert S; Vootiprux V; Cheirsilpa A; Azhar T; Reksodiputro AH
    Cancer; 1998 Dec; 83(11):2270-83. PubMed ID: 9840526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Hu W; Ding W; Yang H; Shao M; Wang B; Wang J; Wu S; Wu S; Jin L; Ma CC
    Radiother Oncol; 2009 Dec; 93(3):488-91. PubMed ID: 19679366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
    Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
    Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
    Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
    Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma.
    Lin JC; Wang WY; Chen KY; Wei YH; Liang WM; Jan JS; Jiang RS
    N Engl J Med; 2004 Jun; 350(24):2461-70. PubMed ID: 15190138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma.
    Al-Amro A; Al-Rajhi N; Khafaga Y; Memon M; Al-Hebshi A; El-Enbabi A; El-Husseiny G; Radawi A; Belal A; Allam A; El-Sebaie M
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):508-13. PubMed ID: 15890594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials.
    Kong L; Hu C; Niu X; Zhang Y; Guo Y; Tham IW; Lu JJ
    Cancer; 2013 Dec; 119(23):4111-8. PubMed ID: 24037893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma.
    Chan AT; Teo PM; Leung TW; Leung SF; Lee WY; Yeo W; Choi PH; Johnson PJ
    Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):569-77. PubMed ID: 7558945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study.
    Fountzilas G; Tolis C; Kalogera-Fountzila A; Karanikiotis C; Bai M; Misailidou D; Samantas E; Athanassiou E; Papamichael D; Tsekeris P; Catodritis N; Nicolaou A; Plataniotis G; Makatsoris T; Papakostas P; Zamboglou N; Daniilidis J
    Strahlenther Onkol; 2005 Apr; 181(4):223-30. PubMed ID: 15827691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Weekly paclitaxel with concurrent intensity-modulated radiotherapy for nasopharyngeal carcinoma: outcomes of a tolerance trial].
    Chen CY; Lu TX; Zhao C; Lu LX; Han F; Sun Y
    Ai Zheng; 2007 Apr; 26(4):398-402. PubMed ID: 17430660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC).
    De Candis D; Stani SC; Bidoli P; Bedini VA; Potepan P; Navarria P; Aglione S; Bajetta E
    Am J Clin Oncol; 2003 Jun; 26(3):265-9. PubMed ID: 12796598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locoregionally advanced nasopharyngeal carcinoma: induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin: a phase II study.
    Ferrari D; Chiesa F; Codecà C; Calabrese L; Jereczek-Fossa BA; Alterio D; Fiore J; Luciani A; Floriani I; Orecchia R; Foa P
    Oncology; 2008; 74(3-4):158-66. PubMed ID: 18714164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.